Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00471419 · ClinicalTrials.gov registry record · Phase 3
Phase II Study of AL-2178 (FID 109980) in the Treatment of Dry Eye
A Phase 3 study, sponsored by Alcon Research.
- Completed
- Registry status
- Phase 3
- Development phase
- 750
- Enrollment target
NCT00471419: Completed Phase 3 study, sponsored by Alcon Research.
NCT00471419 is a Phase 3 study that has completed, run by Alcon Research. The registered enrollment target is 750 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00471419, a Phase 3 study, has completed, sponsored by Alcon Research.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 750 participants
- Enrollment target
Study Summary
The purpose of this study is to see if Rimexolone (FID 109980) is a safe and effective treatment of dry eye.
Interventions
- DRUG Rimexolone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 750 participants |
| Start Date | 2006-07 |
| Est. Completion | 2007-08 |
| Phase | Phase 3 |
What the finished NCT00471419 record still lists
NCT00471419 is an interventional study that assigns participants to a tested intervention. The registered 750 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 0 conditions, and to 1 intervention - of which Rimexolone is the first listed.
NCT00471419 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00471419 about?
NCT00471419 is a clinical study titled "Phase II Study of AL-2178 (FID 109980) in the Treatment of Dry Eye". The purpose of this study is to see if Rimexolone (FID 109980) is a safe and effective treatment of dry eye.
What is the current status of trial NCT00471419?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 750 participants. The study started on 2006-07. Estimated completion is 2007-08.
What interventions are being tested in trial NCT00471419?
The interventions under investigation include: Rimexolone (DRUG).
Who is sponsoring clinical trial NCT00471419?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00471419's enrollment target sits among peer trials
750 464th of 2000 higher than 1,529 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02048332 · 750 participants · Phase 1
Donor-Derived Viral Specific T-cells (VSTs)
- NCT02087852 · 750 participants
Kidney Cancer DNA Registry
- NCT02532452 · 750 participants · Phase 2
Third Party Viral Specific T-cells (VSTs)
- NCT03126916 · 750 participants · Phase 3
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia